Related Experiment Videos

Myricetin protects cardiomyocytes from LPS-induced injury

S Chen1, B Fan2

  • 1School of Pharmacy, Hubei University of Science and Technology, 437100, Hubei Xianning, China.

Herz
|March 31, 2017
PubMed
Abstract

Insights

Myricetin protects against sepsis-induced heart injury by reducing inflammation and oxidative stress. It inhibits the NF-κB pathway, decreasing inflammatory markers and reactive oxygen species in cardiomyocytes.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Pharmacology

Background:

  • Sepsis-induced cardiomyopathy is a significant cause of mortality.
  • Myricetin exhibits anti-inflammatory and anti-oxidative properties.
  • Its role in endotoxin-induced cardiomyopathy is not well understood.

Purpose of the Study:

  • To investigate the protective effects of myricetin against lipopolysaccharide (LPS)-induced cardiomyocyte injury.
  • To elucidate the underlying mechanisms of myricetin's action in vitro.

Main Methods:

  • Assessed mRNA and protein expression of inflammatory cytokines (IL-1beta, IL-6, TNF-alpha) and NF-κB/p65 signaling.
  • Utilized immunofluorescence to track p65 nuclear translocation.
  • Measured oxidative stress markers and apoptosis (TUNEL assay) in H9c2 cardiomyocytes.

Main Results:

  • Myricetin significantly reduced the overexpression of IL-1beta, IL-6, and TNF-alpha by inhibiting the NF-κB/P65 pathway.
  • Myricetin treatment decreased reactive oxygen species (ROS) and enhanced antioxidant enzyme expression.
  • Apoptosis was rarely observed in myricetin-treated cardiomyocytes.

Conclusions:

  • Myricetin demonstrates protective effects against endotoxin-induced early inflammatory responses in cardiomyocytes.
  • These protective effects involve the regulation of ROS and the IκB/NF-κb signaling pathway.
  • Myricetin shows potential as a therapeutic agent for sepsis-related cardiac complications.

Related Concept Videos